November 8, 2011
Opexa (OPXA) Tovaxin® granted FDA Fast Track Designation for MS
November 3, 2011
Verastem files for $50M IPO
October 21, 2011
Athersys (ATHX) and Fast Forward enter Collaboration to treat Multiple Sclerosis
October 19, 2011
RegMed Daily, Mid-Day, 10/19/11, my newest relief, EU markets close at 11:30am, EST each day
October 17, 2011
Athersys (ATHX) completion of P1 Patient Enrollment for Hematopoietic Stem Cell Transplant Trial
October 14, 2011
RegMed Daily, Mid-Day, 10/14/11, perception is reality in this market
October 11, 2011
RegMed Daily, Mid-Day, 10/11/11, markets are nervous and threaten by minny mouse countries
September 26, 2011
RegMed Daily, Mid-Day, 9/26/11, seeing signs of life
August 31, 2011
RegMed Daily Dialogue, 8/31/11, goodbye to August, worried about the historically cruel September
August 29, 2011
RegMed Daily Dialogue, 8/29/11, post excessive sell-off and hurricane, September is still in the wind
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.